📊 ELDN Key Takeaways
Is ELDN a Good Investment? Thesis Analysis
Eledon Pharmaceuticals is a pre-revenue clinical-stage pharmaceutical company with severe cash burn and unsustainable operating losses. The company is burning through cash at an annual rate of $62.3M while generating zero revenue, with current cash reserves of only $22.8M providing minimal runway. The negative profitability metrics and substantial accumulated losses indicate the company is not yet at commercial viability and faces significant execution risk.
Why Buy ELDN? Key Strengths
- Strong liquidity position with 7.40x current ratio providing short-term solvency buffer
- Minimal leverage with 0.00x debt-to-equity ratio reducing financial stress from debt obligations
- Reasonable balance sheet with $169.0M in total assets and positive stockholders equity of $81.1M
ELDN Investment Risks to Consider
- Zero revenue generation indicates no approved commercial products or sales traction
- Severe negative operating cash flow of -$62.3M annually with only $22.8M cash reserves suggests <5 months of runway without additional funding
- Consistent operating losses of -$45.6M and negative ROE of -56.3% demonstrate the company is value-destructive and far from profitability
- Pre-revenue stage implies all value depends on successful drug development and FDA approval with inherent binary outcome risk
- Significant ongoing cash burn rate unsustainable without successful capital raises or major clinical trial success
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestones for pipeline products
- Capital raise activity and equity dilution from future financing rounds
ELDN Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.40x current ratio provides a solid financial cushion.
ELDN Profitability Ratios
ELDN vs Healthcare Sector
How Eledon Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELDN Overvalued or Undervalued?
Based on fundamental analysis, Eledon Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELDN Balance Sheet & Liquidity
ELDN 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Eledon Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.66 indicates the company is currently unprofitable.
ELDN Growth Metrics (YoY)
ELDN Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2017 | N/A | -$3.9M | N/A |
| Q3 2016 | N/A | -$9.3M | N/A |
| Q2 2016 | N/A | -$9.0M | N/A |
| Q1 2016 | N/A | -$11.4M | N/A |
| Q3 2015 | N/A | -$6.4M | N/A |
| Q2 2015 | N/A | -$5.9M | N/A |
| Q1 2015 | N/A | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELDN Capital Allocation
ELDN SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Eledon Pharmaceuticals, Inc. (CIK: 0001404281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELDN
What is the AI rating for ELDN?
Eledon Pharmaceuticals, Inc. (ELDN) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELDN's key strengths?
Claude: Strong liquidity position with 7.40x current ratio providing short-term solvency buffer. Minimal leverage with 0.00x debt-to-equity ratio reducing financial stress from debt obligations.
What are the risks of investing in ELDN?
Claude: Zero revenue generation indicates no approved commercial products or sales traction. Severe negative operating cash flow of -$62.3M annually with only $22.8M cash reserves suggests <5 months of runway without additional funding.
What is ELDN's revenue and growth?
Eledon Pharmaceuticals, Inc. reported revenue of $0.0.
Does ELDN pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ELDN SEC filings?
Official SEC filings for Eledon Pharmaceuticals, Inc. (CIK: 0001404281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELDN's EPS?
Eledon Pharmaceuticals, Inc. has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELDN a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Eledon Pharmaceuticals, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELDN stock overvalued or undervalued?
Valuation metrics for ELDN: ROE of -56.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELDN stock in 2026?
Our dual AI analysis gives Eledon Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELDN's free cash flow?
Eledon Pharmaceuticals, Inc.'s operating cash flow is $-62.3M, with capital expenditures of $17.0K.
How does ELDN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -56.3% (avg: 15%), current ratio 7.40 (avg: 2).